

# Klas Erik Bratteby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7626678/publications.pdf>

Version: 2024-02-01

8  
papers

154  
citations

1307594

7  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in Pretargeted <i>In Vivo</i> Chemistry. ACS Pharmacology and Translational Science, 2021, 4, 824-833.	4.9	45
2	Development of the First Aliphatic <sup>18</sup> F-Labeled Tetrazine Suitable for Pretargeted PET Imaging—Expanding the Bioorthogonal Tool Box. Journal of Medicinal Chemistry, 2021, 64, 15297-15312.	6.4	25
3	Insights into Elution of Anion Exchange Cartridges: Opening the Path toward Aliphatic <sup>18</sup> F-Radiolabeling of Base-Sensitive Tracers. ACS Pharmacology and Translational Science, 2021, 4, 1556-1566.	4.9	20
4	<i>In Vivo Veritas</i> : <sup>18</sup> F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 747-755.	6.4	18
5	Development of <sup>18</sup> F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging. Pharmaceuticals, 2022, 15, 245.	3.8	14
6	Quantitative Mass Spectrometry To Study Inflammatory Cartilage Degradation and Resulting Interactions with the Complement System. Journal of Immunology, 2016, 197, 3415-3424.	0.8	13
7	Aliphatic <sup>18</sup> F-Radiofluorination: Recent Advances in the Labeling of Base-Sensitive Substrates**. ChemMedChem, 2021, 16, 2612-2622.	3.2	13
8	Fully Automated GMP-Compliant Synthesis of [ <sup>18</sup> F]FE-PE2I. Pharmaceuticals, 2021, 14, 601.	3.8	4